Triple-Negative Breast Cancer (TNBC) Recruiting Phase 2 Trials for Olaparib (DB09074)

Also known as: Triple-negative Breast Cancer

IndicationStatusPhase
DBCOND0067309 (Triple-Negative Breast Cancer (TNBC))Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03801369Olaparib and Durvalumab to Treat Patients With Metastatic Triple Negative Breast CancerTreatment